

## Does Radiotherapy Have Consequences on Plasma Concentration of Toxic Pollutants?

C. Charlier,<sup>1</sup> M.-T. Closon,<sup>2</sup> G. Plomteux<sup>1</sup>

<sup>1</sup> Clinical Toxicology Laboratory, University Hospital, CHU Sart Tilman, B4000 Liege, Belgium

<sup>2</sup> Radiotherapy Department, University Hospital, CHU Sart Tilman, 4000 Liege, Belgium

Received: 29 March 2002/Accepted: 20 August 2002

Polychlorinated biphenyl's (PCBs) and chlorinated pesticides [especially 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE), the major metabolite of 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT)] are persistent compounds, accumulating in adipose tissues because of their solubility in lipids and their inefficient metabolism. In this regard, body weight loss occurring after chemotherapy or radiotherapy could be followed by an increase in blood concentration of potentially toxic pollutants (Chevrier et al. 2000). Confirmation that humans are exposed to chemicals that interfere with the hormonal system (endocrine disrupters) has prompted many epidemiological studies but an association between chemical residues and disease remains elusive. Many publications tend to establish a correlation between organochlorine pesticides in blood or tissues and male reproductive disorders (Aliva et al. 2001), precocious puberty (Krstevska-Konstantinova et al. 2001) or breast cancer (Dewailly et al. 1994; Hoyer et al. 2000), even if the possible etiological role in breast cancer development remains unclear (Zheng et al. 2000; Laden et al. 2001). Retrospective studies usually deserve blame because it is very difficult to set down the cancer development to the plasma concentration of the chemical compound. Indeed, the increased plasma concentration of pollutants could be subsequent to the cancer detection and treatment. The aim of this study was to evaluate the consequences of radiotherapy on plasma concentration of DDT, DDE, hexachlorobenzene (HCB) and PCBs n° 28, 52, 101, 118, 138, 153 and 180 in a group of sixty five cancer patients submitted to radiotherapy. A control group consisting of 55 subjects of similar mean age was also formed in order to compare plasma concentrations.

### MATERIALS AND METHODS

The cases group (Table 1) was constituted of 65 patients suffering from different cancers who were undergoing radiotherapy treatment before or after surgery. Blood samples were collected just before the 1<sup>st</sup> radiation process and in the middle of the last week of treatment. Mean treatment duration was 4 weeks (SD = 1.22 weeks). Body weight was registered at the time of both blood samplings. A control group of 55 healthy individuals of the same age who were tested for plasma concentrations of the same compounds was formed in order to compare

the results (Table 1). For each case or control individual, blood sample was immediately centrifuged and serum was kept frozen at -18°C until assay.

**Table 1.** Characteristics of the subjects (n=65) and controls (n=55)

|                          | Subjects    | Controls     |
|--------------------------|-------------|--------------|
| Age (y)                  | 62.7 ± 12.9 | 57.49 ± 12.6 |
| BMI (kg/m <sup>2</sup> ) |             | 22.90 ± 6.8  |
| Prior to radiotherapy    | 22.6 ± 5.2  |              |
| At the end of treatment  | 22.0 ± 5.8  |              |

---

Values are means ± SD

---

All people gave their informed consent for participating in the study.

The identification and quantification of chlorinated hydrocarbons (DDE, DDT, HCB) and PCBs (congeners n°s 28, 52, 101, 118, 138, 153 and 190) in serum were done using a gas chromatographic analyser coupled to a Tandem mass spectrometer detector. Briefly, sample preparation included a liquid-liquid extraction (petroleum ether: diethylether, 98:2) followed by a solid-phase extraction (Bond Elut Certify, Varian). The eluate was evaporated to dryness, reconstituted in n-hexane and then injected into the gas chromatograph (Saturn 2000, Varian). The column was a HP-5 Trace from Agilent (30 m x 0.25 mm internal diameter). Ionisation by electronic impact occurred at 70eV. All solvents were pesticide-grade quality. Reference standards of all compounds were obtained from Cambridge Isotope Laboratories (Andover, MA, USA) or Dr Ehrenstorfer (Ausburg, Germany). The calibration curve was constructed from 0 to 30 ppb and linearity applied for this concentration range. Endosulfan-d4 (0.5 ppb) was used as internal standard. Limits of quantification were defined as ten times the standard deviation (SD) of the results from the lowest quality-control serum pool over the course of the analyses (n=15). These limits were approximately 0.5 ppb for organochlorines and 2 ppb for PCBs.

Samples were analysed in a blind procedure together with controls consisting of samples spiked with 2 or 5 ppb of each compound tested. Results were corrected for total lipid content calculated by the recommended method (Patterson et al. 1991) after total cholesterol, free cholesterol, phospholipids and triglycerides measurements were conducted using standard enzymatic procedure on a MEGA chemistry analyser.

In paired samples (before and after radiotherapy), the blood levels of chlorinated adjusted for total lipids were compared using Student's *t*-test after normalization of the data's distribution. The same test was used to compare cancer subjects with control group. Spearman's correlation coefficient was used to assess the relationship between body weight loss during radiotherapy and changes in pollutant concentration. All results were considered to be significant at the 5 % critical level ( $p < 0.05$ ).

## RESULTS AND DISCUSSION

The results for all detected compounds are presented in Table 2.

The most frequent organochlorine residue was pp'DDE. HCB was also detected with a high frequency. The PCBs n° 28, 153 and 138 were more often present than not. Only PCB n°52 was never detected in these two groups.

Body weight loss was not important during radiotherapy, and no significant changes were found between the beginning and the end of the treatment. However, the plasma organochlorine concentration was significantly higher in this population than in controls (Table 3).

**Table 2.** Plasma organochlorines and PCBs prevalence and concentrations in cancer subjects before (Pre) and after (Post) radiotherapy, and in control subjects. Values are means  $\pm$  SD.

| Compounds | Cancer subjects : Pre (n = 65) |   | Cancer subjects : Post (n = 65) |   |
|-----------|--------------------------------|---|---------------------------------|---|
|           | Prevalence (%)                 | Concentration ( $\mu\text{g/g lipid}$ ) | Prevalence (%)                  | Concentration ( $\mu\text{g/g lipid}$ ) |
| pp'DDE    | 92.3                           | $3.05 \pm 1.02$                         | 92.8                            | $3.03 \pm 1.00$                         |
| pp'DDT    | 10.4                           | $1.24 \pm 0.20$                         | 10.4                            | $1.23 \pm 0.18$                         |
| HCB       | 24.6                           | $1.40 \pm 0.09$                         | 25.0                            | $1.49 \pm 0.11$                         |
| PCB 28    | 34.8                           | $0.84 \pm 0.12$                         | 34.8                            | $0.87 \pm 0.13$                         |
| PCB 52    | 0                              | -                                       | 0                               | -                                       |
| PCB 101   | 10.8                           | $0.32 \pm 0.07$                         | 10.4                            | $0.31 \pm 0.08$                         |
| PCB 118   | 12.9                           | $0.94 \pm 0.11$                         | 12.9                            | $1.02 \pm 0.08$                         |
| PCB 138   | 27.6                           | $0.62 \pm 0.05$                         | 27.6                            | $0.67 \pm 0.08$                         |
| PCB 153   | 30.2                           | $0.46 \pm 0.06$                         | 31.0                            | $0.43 \pm 0.10$                         |
| PCB 180   | 14.5                           | $0.39 \pm 0.07$                         | 14.5                            | $0.39 \pm 0.12$                         |

  

| Control subjects (n = 55) |                |   |
|---------------------------|----------------|---|
| Compounds                 | Prevalence (%) | Concentration ( $\mu\text{g/g lipid}$ ) |
| pp'DDE                    | 90.4           | $1.74 \pm 0.85$                         |
| pp'DDT                    | 1.0            | $1.00 \pm 0.06$                         |
| HCB                       | 17.0           | $0.94 \pm 0.10$                         |
| PCB 28                    | 30.0           | $0.51 \pm 0.07$                         |
| PCB 52                    | 0              | -                                       |
| PCB 101                   | 6.0            | $0.17 \pm 0.07$                         |
| PCB 118                   | 7.0            | $0.78 \pm 0.12$                         |
| PCB 138                   | 19.0           | $0.31 \pm 0.18$                         |
| PCB 153                   | 22.8           | $0.32 \pm 0.09$                         |
| PCB 180                   | 6.0            | $0.31 \pm 0.08$                         |

**Table 3.** Correlation's between changes in body weight and plasma concentrations in cancer patients and comparison between plasma concentrations in cancer patients (Pre and Post) and control subjects. NS: non-significant.

| Compounds | Correlation's (r <sup>2</sup> )<br>with body weight loss | Comparison (p)<br>with control subjects |        |
|-----------|--|---|--------|
|           |  | Pre                                     | Post   |
| pp'DDE    | NS   | 0.0008                                  | 0.0008 |
| pp'DDT    | NS   | NS                                      | NS     |
| HCB       | NS   | 0.0032                                  | 0.0036 |
| PCB 28    | NS   | 0.0245                                  | 0.0270 |
| PCB 101   | NS   | 0.0030                                  | 0.0030 |
| PCB 118   | NS   | 0.0016                                  | 0.0020 |
| PCB 138   | NS   | 0.0024                                  | 0.0026 |
| PCB 153   | NS   | 0.0027                                  | 0.0032 |
| PCB 180   | NS   | 0.0003                                  | 0.0003 |

Bioaccumulation of HCB, DDT, DDE and PCBs in human tissues is known to be correlated with age but this positive correlation is not sufficient to explain the significant difference between cases and controls in this study, since the mean ages are comparable between both groups. Additional follow-up studies are necessary to explain why the level of pollutants in the cancer group is higher than in the control subjects. Possible reasons are a significant body weight loss due to surgery, chemotherapy or to the cancer process (Wolff et al.1995; Chevrier et al. 2000; Wolff et al.2000). A retrospective examination of all patients' history could permit to evaluate the current presence of such xenobiotics in plasma but also its possible impact on human health. However, it can be concluded from the presented data that radiotherapy associated body weight loss is not significant enough to increase the plasma concentration of these chemical compounds.

## REFERENCES

- Aliva A, Spira A, Multigner L (2001) Contribution of environmental factors to the risk of male infertility. *Hum Reprod* 16 : 1768-1776
- Chevrier J, Dewailly E, Ayotte P, Mauriège P, Després J-P, Tremblay A (2000) Body weight loss increases plasma and adipose tissue concentrations of potentially toxic pollutants in obese individuals. *Int J Obesity* 24 : 1272-1278
- Dewailly E, Dodin S, Verreault R, Ayotte P, Sauvé L, Morin J, Brisson J (1994) High organochlorine body burden in women with estrogen receptor-positive breast cancer. *J Natl Cancer Inst* 86 : 232-234
- Hoyer AP, Jorgensen T, Brock JW, Grandjean P (2000) Organochlorine exposure and breast cancer survival. *J Clin Epidemiol* 53 : 323-330
- Krstevska-Konstantinova M, Charlier C, Craen M, Du Caju M, Heinrichs C, de Beaufort C, Plomteux G, Bourguignon JP (2001) Sexual precocity after immigration from developing countries to Belgium : evidence of previous exposure to organochlorine pesticides. *Hum Reprod* 16 : 1020-1026
- Laden F, Hankinson SE, Wolff M, Colditz G, Willett W, Speizer F, Hunter D (2001) Plasma organochlorine levels and the risk of breast cancer : an

- extended follow-up in the Nurses' Health Study. *Int J Cancer* 91 : 568-574
- Patterson DG, Isaacs SG, Alexander LR, Turner WE, Hampton L, Bernert JT, Needham LL (1991) Method 6 : determination of specific polychlorinated dibenzo-P-dioxins and dibenzofurans in blood and adipose tissue by isotope dilution-high resolution mass spectrometry. *International Agency for Research on Cancer Sci Publ* 108: 299-342
- Wolff MS, Toniolo PG (1995) Environmental organochlorine exposure as a potential etiologic factor in breast cancer. *Environ Health Perspect* 103 : 141-145
- Wolff MS, Zeleniuch-Jacquotte A, Dubin N, Toniolo P (2000) Risk of breast cancer and organochlorine exposure. *Cancer Epidemiol Biomarkers Prev* 9 : 271-277
- Zheng T, Holford TR, Tessari J, Mayne ST, Owens PH, Ward B, Carter D, Boyle P, Dubrow R, Archibeque-Engle S, Zahm SH (2000) Breast cancer risk associated with congeners of polychlorinated biphenyls. *American J Epidemiol* 152 : 50-58